The role of Plk3 in oncogenesis

Area of Science:

• Molecular Biology
• Cell Biology
• Cancer Research

Background:

• Polo-like kinases (Plks) are serine/threonine protein kinases crucial for cell cycle control, mitosis, DNA replication, and stress responses.
• Plk1 is a validated cancer target, with inhibitors like volasertib (BI 6727) showing therapeutic potential, including FDA breakthrough therapy designation for acute myeloid leukemia.
• However, ATP-competitive Plk1 inhibitors can also affect Plk2 and Plk3, which function as tumor suppressors.

Purpose of the Study:

• To highlight the critical roles of Plk3 in cell cycle regulation, apoptosis, and cellular stress.
• To emphasize the need to consider the biological functions of Plk3 when developing Plk1 inhibitors for cancer therapy.
• To underscore the implications of Plk1 inhibitor off-target effects on tumor suppressor Plk3 in cancer treatment strategies.

Main Methods:

• Review of existing literature on polo-like kinase family members, focusing on Plk1 and Plk3.
• Analysis of the cellular processes regulated by Plk3, including cell cycle control, apoptosis, and stress signaling.
• Examination of the impact of ATP-competitive Plk1 inhibitors on Plk3 activity and cancer cell biology.

Main Results:

• Plk3 plays a significant role in cell cycle progression, apoptosis, and response to cellular stress.
• Aberrant expression of Plk3 is observed in various tumor types, suggesting its involvement in tumorigenesis.
• ATP-competitive Plk1 inhibitors, while targeting cancer, may inadvertently inhibit tumor-suppressive Plk3 functions.

Conclusions:

• Understanding the dual role of Plk family members is crucial for effective cancer therapy.
• The inhibition of Plk3 by Plk1-targeting drugs necessitates careful evaluation to optimize cancer treatment strategies.
• Further research into the specific roles of Plk3 in tumorigenesis and its interaction with Plk1 inhibitors is warranted.